Menu
Recruiting NCT04658628

Brain Imaging Biomarkers for Response to Spinal Cord Stimulation in Patients With Chronic Low Back Pain

Observational Chronic Low-back Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Chronic Low-back Pain. Basic parameters: from 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

In this protocol, "Brain imaging biomarkers for response to Spinal Cord Stimulation in patients with chronic low back pain," the investigators plan to perform brain mapping studies in 42 patients who are undergoing spinal cord stimulation (SCS) for chronic low back pain (CLBP) as part of the participants normal clinical care during a 2-year period. This imagining study is completed for research purposes. There is no standard of care imaging for the participants. This study requires two visits in total. During the baseline visit, participants will undergo imaging acquisition protocol and corresponding assessments. Participants will have another follow-up visit (potentially remotely) for final assessments two weeks after the SCS treatment. The objective of the study is to investigate potential imaging biomarkers that can predict response to the SCS treatment. Specifically, the investigators hypothesize that the connectivity of a certain region of the brain (specifically the subgenual cingulate) prior to SCS may serve as a possible pre-operative imaging-based biomarker on response to SCS. The findings of the study may further enhance investigators understanding of the connectivity between brain areas that are critical to the therapeutic response to SCS in CLBP patients and that can be used as a putative biomarker to select patients who may respond to SCS.

Primary outcome measures

  • Change in VAS [Time frame: Baseline and 2 weeks]
  • Change in HAMD-17 [Time frame: Baseline and 2 weeks]
  • Change in MPQ [Time frame: Baseline and 2 weeks]
  • Change in PASS [Time frame: Baseline and 2 weeks]

Eligibility criteria

Inclusion criteria

  • Male or female ≥ 21 years of age at time of consent
  • Subject has been recommended to undergo an SCS trial for chronic back with or without leg pain by their pain management physician
  • Chronic low back pain as defined by persistent low back pain despite prior treatments that continues for 12 weeks or longer
  • Subject signs a valid, Institutional Review Board (IRB)-approved informed consent form (ICF) provided

Exclusion criteria

  • Subject is a woman who is not using adequate contraception, is pregnant or breastfeeding or intends to become pregnant during the course of the study
  • Subject has previously undergone a spinal cord stimulation trial or is already implanted with an active implantable device(s) to treat their pain (Implantable Pulse Generators (IPGs), implantable drug pump, etc.) or pacemaker or implantable cardiac defibrillator
  • Subject is currently abusing alcohol or illicit drugs
  • Contraindications to MRIs or the need for recurrent body MRIs
  • Presence of cardiac pacemakers/defibrillators, implanted medication pumps, intra-cardiac lines, any intracranial implants (e.g., aneurysm clip, shunt, cochlear implant, electrodes) or other implanted stimulators

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • University of California Los Angeles — Los Angeles

Identifiers

NCT: NCT04658628 · IRB#20-001870

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗